Clinical Trial Update: ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab [Phase 4]

View source ↗

Summary

Phase 4 study evaluating ctDNA-guided addition of ipilimumab to patients receiving nivolumab and relatlimab for metastatic or advanced melanoma; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)
• Yervoy (ipilimumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Metastatic Melanoma, Advanced Melanoma | Phase 4 | Status: RECRUITING